SCHEMBL14715718

SCHEMBL14715718

CSc1ccc(Nc2ncc(C(c3c[nH]c4ncc(C)cc34)S(=O)(=O)c3ccccc3)cn2)cc1

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.32
CYP3A4 P08684 2/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
AAK1 Q2M2I8 1/20 0.31
PIK3CA P42336 2/20 0.31
ALDH1A1 P00352 2/20 0.31
MET P08581 1/20 0.31
PSEN1 P49768 1/20 0.30
PSEN2 P49810 1/20 0.30
APH1B Q8WW43 1/20 0.30
NCSTN Q92542 1/20 0.30
APH1A Q96BI3 1/20 0.30
PSENEN Q9NZ42 1/20 0.30
HTR1A P08908 1/20 0.30
HTR2A P28223 1/20 0.30
HTR7 P34969 1/20 0.30
HTR6 P50406 1/20 0.30
PLK1 P53350 1/20 0.30
MEN1 O00255 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2545189 0.89 PTGS2 (0.36) AAK1PLK1GSK3B
SCHEMBL2542238 0.70 CYP3A4 (0.58) CYP3A4CYP2C9CYP2C19
SCHEMBL4512512 0.69 CYP2C9 (0.42) CYP3A4CYP2C9CYP2C19AAK1PIK3CA
SCHEMBL2540264 0.68 JAK2 (0.37) PIK3CAGSK3B
SCHEMBL12140781 0.68 CYP3A4 (0.37) CYP3A4CYP2C9CYP2C19AAK1PIK3CA
SCHEMBL1266809 0.66 JAK2 (0.43) CYP3A4CYP2C9PIK3CAMETGSK3B
SCHEMBL12258418 0.66 BRD4 (0.39) KDM1ACYP3A4CYP2C9CYP2C19PSEN1
SCHEMBL12140733 0.65 AXL (0.39) CYP3A4CYP2C9CYP2C19MAPTGSK3B
SCHEMBL12140726 0.65 AXL (0.39) CYP3A4CYP2C9CYP2C19MAPTGSK3B
SCHEMBL12140715 0.65 AXL (0.39) CYP3A4CYP2C9CYP2C19MAPTGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170283423-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2017-10-05 US disclosed
EP-2560972-B1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC (US) 2017-09-20 EP disclosed
US-9682981-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2017-06-20 US disclosed
US-20150183793-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR Opna Bio SA (CH) 2015-07-02 US disclosed
US-8901118-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2014-12-02 US disclosed
EP-2560972-A2 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR Plexxikon, Inc. (US) 2013-02-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170283423-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR FLT3, PRKDC, NTRK1 KDM1A 3797/4885CYP3A4 3835/4885CYP2C9 3333/4885
US-20150183793-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR FLT3, PRKDC, NTRK1 KDM1A 3545/4885CYP3A4 3841/4885CYP2C9 3493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.